GenVec (GNVC) versus The Competition Financial Contrast
GenVec (NASDAQ: GNVC) is one of 187 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare GenVec to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.
Valuation and Earnings
This table compares GenVec and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|GenVec Competitors||$217.29 million||-$39.39 million||-53.99|
Insider and Institutional Ownership
6.2% of GenVec shares are held by institutional investors. Comparatively, 48.2% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 8.1% of GenVec shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares GenVec and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations for GenVec and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
GenVec presently has a consensus target price of $7.00, indicating a potential downside of 2.64%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.16%. Given GenVec’s competitors stronger consensus rating and higher possible upside, analysts clearly believe GenVec has less favorable growth aspects than its competitors.
GenVec competitors beat GenVec on 9 of the 11 factors compared.
GenVec Company Profile
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Receive News & Ratings for GenVec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec and related companies with MarketBeat.com's FREE daily email newsletter.